WWL113
|
|
|
- CAS號(hào):
- 947669-86-5
- 英文名:
- WWL113
- 英文別名:
- WWL113;WWL-113,WWL113;AKIIPHDGVCFVCC-UHFFFAOYSA-N;ethyl 4-[4-[methyl-[(3-pyridin-4-ylphenyl)methyl]carbamoyl]oxyphenyl]benzoate;4'-[[[Methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-[1,1'-biphenyl]-4-carboxylic acid ethyl ester;[1,1'-Biphenyl]-4-carboxylic acid, 4'-[[[methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-, ethyl ester
- 中文名:
- WWL113
- 中文別名:
- 化合物 WWL113;化合物 T17259;化合物：WWL113 CAS:947669-86-5;化合物:WWL113 CAS:947669-86-5
- CBNumber:
- CB23067596
- 分子式:
- C29H26N2O4
- 分子量:
- 466.52774
- MOL File:
- 947669-86-5.mol
|
|
|
WWL113化學(xué)性質(zhì)
-
沸點(diǎn):
-
630.9±55.0 °C(Predicted)
-
|
-
密度:
-
1+-.0.06 g/cm3(Predicted)
-
|
-
儲(chǔ)存條件:
-
Store at -20°C
-
|
-
溶解度:
-
DMF: 25 mg/ml; DMF:PBS(pH7.2) (1:2): 0.3 mg/ml; DMSO: 15 mg/ml; Ethanol: 0.1 mg/ml
-
|
-
形態(tài):
-
A crystalline solid
-
|
-
酸度系數(shù)(pKa):
-
5.18±0.26(Predicted)
-
|
-
顏色:
-
White to off-white
-
|
-
InChI:
-
1S/C29H26N2O4/c1-3-34-28(32)25-9-7-22(8-10-25)23-11-13-27(14-12-23)35-29(33)31(2)20-21-5-4-6-26(19-21)24-15-17-30-18-16-24/h4-19H,3,20H2,1-2H3
-
|
-
InChIKey:
-
AKIIPHDGVCFVCC-UHFFFAOYSA-N
-
|
-
SMILES:
-
CCOC(C(C=C1)=CC=C1C(C=C2)=CC=C2OC(N(C)CC3=CC(C4=CC=NC=C4)=CC=C3)=O)=O
-
|
WWL113性質(zhì)、用途與生產(chǎn)工藝
WWL113 是具有口服活性的、選擇性的 Ces3 和 Ces1f 的抑制劑，其對(duì) Ces3 和 Ces1f 的 IC50 值分別為 120 nM 和 100 nM。WWL113 對(duì) 60-kDa絲氨酸水解酶(或水解酶)有極好的選擇性。
IC50: 120 nM (Ces3), 100 nM (Ces1f).
Ces3 and Ces1f are endoplasmic reticulum glycoproteins that have been previously associated with adipocyte lipolysis. WWL113 inhibits mouse recombinant Ces1, Ces1c, and ABHD6 at 10 μM.
WWL113 (1 μM) significantly increases UCP1 protein expression in brown adipocytes.
WWL113 has a partial, statistically significant inhibitory effect on blocking the buildup of PGE2.
WWL113 (30 mg/kg, orally once a day) results in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance.
WWL113 ameliorates obesity-diabetes in mice.
|
Animal Model:
|
Eight-week-old db/db mice (n = 10 per group).
|
|
Dosage:
|
30 mg/kg.
|
|
Administration:
|
Orally once a day for 3 weeks.
|
|
Result:
|
Corrected multiple features of metabolic syndrome in db/db mice.
|
WWL113
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS編號(hào) | 包裝 | 價(jià)格 |
|---|
| 2026/06/05 | HY-110148 | WWL113
WWL113 | 947669-86-5 | 5 mg | 800元 |
| 2026/06/05 | HY-110148 | WWL113 | 947669-86-5 | 10 mM * 1 mLin DMSO | 821元 |
947669-86-5, WWL113 相關(guān)搜索:
- 抑制劑
- 化合物：WWL113 CAS:947669-86-5
- 化合物:WWL113 CAS:947669-86-5
- 化合物 WWL113
- 化合物 T17259
- 947669-86-5
- [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[[methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-, ethyl ester
- WWL-113,WWL113
- 4'-[[[Methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-[1,1'-biphenyl]-4-carboxylic acid ethyl ester
- ethyl 4-[4-[methyl-[(3-pyridin-4-ylphenyl)methyl]carbamoyl]oxyphenyl]benzoate
- AKIIPHDGVCFVCC-UHFFFAOYSA-N
- WWL113